Article    Table of Contents                    Full Text of this article Free    Figures/Tables List    Related articles in Annals  Services    Send comment/rapid response letter    Notify a friend about this article    Alert me when this article is cited    Add to Personal Archive    Download to Citation Manager    ACP Search                            Get Permissions  Google Scholar    Search for Related Content  PubMed Articles in PubMed by Author:    Klinkenberg-Knol, E. C.    Meuwissen, S. G. M.    Related Articles in PubMed    PubMed Citation    PubMed

ARTICLE

Long-Term Treatment with Omeprazole for Refractory Reflux Esophagitis: Efficacy and Safety

Elly C. Klinkenberg-Knol; Henk P. M. Festen; Jan B. M. J. Jansen; Cornelis B. H. W. Lamers; Frits Nelis; Pleun Snel; Anton Luckers; Cornelius P. M. Dekkers; Niilo Havu; and Stephan G. M. Meuwissen

1 August 1994 | Volume 121 Issue 3 | Pages 161-167

Objective: To evaluate the long-term efficacy and safety of omeprazole in patients with gastroesophageal reflux disease resistant to treatment with histamine-2 (H₂)-receptor antagonists.

Design: Cohort analytic study with a mean follow-up of 48 months (range, 36 to 64 months).

Setting: Patients receiving ambulatory care from referral centers.

Patients: 91 patients with gastroesophageal reflux disease resistant to treatment with an H₂-receptor antagonist but subsequently responsive to 40 mg of omeprazole daily.

Intervention: Open maintenance therapy consisting of 20 mg of omeprazole daily in 86 patients and 40 mg daily in 5 patients.

Outcome Measures: Endoscopy to assess healing; side effects, laboratory values, fasting serum gastrin level, and gastric corpus biopsies to assess safety.

Results: Esophagitis recurred in 47% of the patients receiving 20 mg of omeprazole daily, but all rehealed after the dose was doubled. Seven of 40 patients (18%) had a second relapse after a mean follow-up time of 24 months (range, 9 to 36 months) that was successfully treated with a further 20-mg dose increment for a mean period of 36 months (range, 6 to 39 months). Median gastrin levels increased initially from 60 ng/L before study entry to 162 ng/L (P < 0.01) with treatment and reached a plateau during maintenance treatment. Very high gastrin levels (>500 ng/L) were observed in a subgroup (11%) of patients. The incidence of micronodular hyperplasia increased from 2.5% of the patients at first biopsy to 20% at the last biopsy (P = 0.001), with a corresponding progression of gastritis to subatrophic or atrophic gastritis from less than 1% to 25% (P < 0.001), which was more pronounced in patients with very high serum gastrin levels.

Conclusions: Maintenance therapy with omeprazole was effective for at least 5 years in patients with gastroesophageal reflux disease resistant to treatment with H₂-receptor antagonists. Treatment was accompanied by a persistent increase in serum gastrin levels and an increase of micronodular argyrophil cell hyperplasia and subatrophic or atrophic gastritis.

Author and Article Information

From the Free University Hospital, Amsterdam; Groot Ziekengasthuis Hertogenbosch; State University, Leiden; Sophia Hospital, Zwolle; Slotervaart Hospital, Amsterdam; Jacobus Hospital, Zwijndrecht; St. Ignatius Hospital, Breda; Catholic University, Nijmegen, the Netherlands; AB Astra, Sodertalje, Sweden.
Requests for Reprints: E. C. Klinkenberg-Knol, MD, PhD, Free University Hospital, Department of Gastroenterology, P.O. Box 7057, 1007 MB Amsterdam, the Netherlands.
Acknowledgments: The authors thank L. Frison, AB Hassle, Goteborg, Sweden, and J. Nauta, Department of Theory of Medicine, Epidemiology and Biostatistics, Free University, Amsterdam, the Netherlands, for performing the statistical analyses.
Grant Support: By AB Hassle, a subsidiary of AB Astra, Sodertalje, Sweden.

Related articles in Annals:

Editorials
Omeprazole, Hypergastrinemia, and Gastric Carcinoid Tumors
James W. Freston

Annals 1994 121: 232-233. [Full Text]  

This article has been cited by other articles:

				E J Kuipers Proton pump inhibitors and gastric neoplasia. Gut, September 1, 2006; 55(9): 1217 - 1221. [Abstract] [Full Text] [PDF]

				E J Kuipers, G F Nelis, E C Klinkenberg-Knol, P Snel, D Goldfain, J J Kolkman, H P M Festen, J Dent, P Zeitoun, N Havu, et al. Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial Gut, January 1, 2004; 53(1): 12 - 20. [Abstract] [Full Text] [PDF]

				L Lundell Laparoscopic fundoplication is the treatment of choice for gastro-oesophageal reflux disease Gut, October 1, 2002; 51(4): 468 - 471. [Full Text] [PDF]

				J Dent Management of reflux disease Gut, May 1, 2002; 50(90004): iv67 - 71. [Abstract] [Full Text] [PDF]

				D. Y. Graham, N. M. Agrawal, D. R. Campbell, M. M. Haber, C. Collis, N. L. Lukasik, and B. Huang Ulcer Prevention in Long-term Users of Nonsteroidal Anti-inflammatory Drugs: Results of a Double-blind, Randomized, Multicenter, Active- and Placebo-Controlled Study of Misoprostol vs Lansoprazole Arch Intern Med, January 28, 2002; 162(2): 169 - 175. [Abstract] [Full Text] [PDF]

				H E Myrvold, L Lundell, P Miettinen, S A Pedersen, B Liedman, J Hatlebakk, R Julkunen, K Levander, M Lamm, C Mattson, et al. The cost of long term therapy for gastro-oesophageal reflux disease: a randomised trial comparing omeprazole and open antireflux surgery Gut, October 1, 2001; 49(4): 488 - 494. [Abstract] [Full Text] [PDF]

				G TRIADAFILOPOULOS Proton pump inhibitors for Barrett's oesophagus Gut, February 1, 2000; 46(2): 144 - 146. [Full Text] [PDF]

				D Gillen, A A Wirz, W D Neithercut, J E S Ardill, and K E L McColl Helicobacter pylori infection potentiates the inhibition of gastric acid secretion by omeprazole Gut, April 1, 1999; 44(4): 468 - 475. [Abstract] [Full Text] [PDF]

				M. H. Kulke and R. J. Mayer Carcinoid Tumors N. Engl. J. Med., March 18, 1999; 340(11): 858 - 868. [Full Text] [PDF]

				T. Lerut Esophageal surgery at the end of the millennium J. Thorac. Cardiovasc. Surg., July 1, 1998; 116(1): 1 - 20. [Full Text]

				A E Berstad, J G Hatlebakk, H Maartmann-Moe, A Berstad, and P Brandtzaeg Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole Gut, December 1, 1997; 41(6): 740 - 747. [Abstract] [Full Text] [PDF]

				E. J. Kuipers, L. Lundell, E. C. Klinkenberg-Knol, N. Havu, H. P.M. Festen, B. Liedman, C. B.H.W. Lamers, J. B.M.J. Jansen, J. Dalenback, P. Snel, et al. Atrophic Gastritis and Helicobacter pylori Infection in Patients with Reflux Esophagitis Treated with Omeprazole or Fundoplication N. Engl. J. Med., April 18, 1996; 334(16): 1018 - 1022. [Abstract] [Full Text] [PDF]

				The medical management of gastro-oesophageal reflux DTB, January 1, 1996; 34(1): 1 - 4. [Abstract] [Full Text] [PDF]

				G.N.J. Tytgat Long-Term Therapy for Reflux Esophagitis N. Engl. J. Med., October 26, 1995; 333(17): 1148 - 1150. [Full Text]

				C. S. Fuchs and R. J. Mayer Gastric Carcinoma N. Engl. J. Med., July 6, 1995; 333(1): 32 - 41. [Full Text] [PDF]

				IS LONG-TERM OMEPRAZOLE SAFE? Journal Watch (General), August 12, 1994; 1994(812): 1 - 1. [Full Text]